Vasopressin and oxytocin in CSF and plasma of patients with aneurysmal subarachnoid haemorrhage

Martin, Jan; Kagerbauer, Simone Maria; Schuster, Tibor; Blobner, Manfred; Kochs, Eberhard; Landgraf, Rainer

doi:10.1016/j.npep.2013.12.004

Cited by 37 publications

(29 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In animal models, the central and peripheral OT systems can communicate with each other and influence behavior through afferent inputs, including the vagal nerve (Brown, Bains, Ludwig, & Stern, 2013). Human correlational studies of endogenous OT levels in plasma and CSF under basal conditions have been contradictory, with one study showing significant correlations in children (Carson et al, 2015), but others showing no significant relationships in adults (Kagerbauer et al, 2013; Martin et al, 2014; Veening, de Jong, & Barendregt, 2010). Regardless of whether peripheral OT is representative of central OT release, the ability of the peripheral OT system to communicate with and influence the central system suggests that plasma OT may be a useful biomarker in human infants if correlated with infant outcomes.…”

Section: Discussionmentioning

confidence: 99%

Plasma and Urinary Oxytocin Trajectories in Extremely Premature Infants During NICU Hospitalization

Weber

Harrison

Sinnott

et al. 2017

Biological Research For Nursing

View full text Add to dashboard Cite

Extremely premature infants are at great risk for poor neurodevelopmental outcomes, in part because neurologic structures designed to mature in the womb must now do so in the extrauterine environment. Reliable biomarkers of neurodevelopment are especially critical in this population, as behavioral measures can be unreliable due to immaturity of the premature infant nervous system. Oxytocin (OT) has the potential to be a marker of neurobiological processes that offer infant neuroprotection. However, no studies have measured OT in the plasma and urine of premature infants. The purposes of this study were to describe plasma and urine OT levels of premature infants through 34 weeks corrected gestational age (CGA), determine whether plasma and urine OT are correlated, and explore associations between infant demographics and OT trajectories. Plasma and urine from 37 premature infants, born at gestational ages 25–28 6/7 weeks, were longitudinally collected at 14 days of life, then weekly until 34 weeks CGA. Plasma OT decreased with age, at a rate of 15% per week, and exhibited strong stability within infants. Urine OT was not correlated with plasma OT and did not show a significant trend over time; thus, urine may not be a reliable, noninvasive measurement in this population. Apgar score was the only infant demographic characteristic associated with plasma OT. Given the novelty of this work, replication is needed to confirm these findings, and future research should explore potential mechanisms (e.g., stress, normal maturation, and social experiences) that contribute to declining plasma OT levels in premature infants.

show abstract

Section: Discussionmentioning

confidence: 99%

Plasma and Urinary Oxytocin Trajectories in Extremely Premature Infants During NICU Hospitalization

Weber

Harrison

Sinnott

et al. 2017

Biological Research For Nursing

View full text Add to dashboard Cite

show abstract

“…Winslow et al measured CSF and plasma oxytocin in rhesus monkeys in a study of the effects of rearing conditions: while CSF oxytocin correlated with social behaviour, plasma levels did not, nor did they correlate with CSF levels collected in the same session (88). CSF and plasma concentrations showed no correlation in patients with aneurysmal subarachnoid haemorrhage (89)…”

Section: Central and Peripheral Release Of Oxytocinmentioning

confidence: 99%

Intranasal Oxytocin: Myths and Delusions

Leng

Ludwig

2016

Biological Psychiatry

518

475

View full text Add to dashboard Cite

Despite widespread reports that intranasal application of oxytocin has a variety of behavioral effects, very little of the huge amounts applied intranasally appears to reach the cerebrospinal fluid. However, peripheral concentrations are increased to supraphysiologic levels, with likely effects on diverse targets including the gastrointestinal tract, heart, and reproductive tract. The wish to believe in the effectiveness of intranasal oxytocin appears to be widespread and needs to be guarded against with scepticism and rigor. Preregistering trials, declaring primary and secondary outcomes in advance, specifying the statistical methods to be applied, and making all data openly available should minimize problems of publication bias and questionable post hoc analyses. Effects of intranasal oxytocin also need proper dose-response studies, and such studies need to include control subjects for peripheral effects, by administering oxytocin peripherally and by blocking peripheral actions with antagonists. Reports in the literature of oxytocin measurements include many that have been made with discredited methodology. Claims that peripheral measurements of oxytocin reflect central release are questionable at best.

show abstract

“…One study demonstrated that neuropeptides Argvasopressin and oxytocin are lower in patients with a poor outcome after SAH, possibly reflecting hypothalamic damage after SAH [8]. Furthermore, plasma levels of visfatin, an adipokine linked with inflammation, have been shown to predict the severity of SAH and have prognostic utility for clinical outcomes [9 ▪ ].…”

Section: Improving Neurological Outcomes After Subarachnoid Hemorrhagementioning

confidence: 99%

Postoperative ICU management of patients after subarachnoid hemorrhage

Gruenbaum

Bilotta²

2014

Current Opinion in Anaesthesiology

View full text Add to dashboard Cite

Purpose of review This article reviews recent advances in the postoperative ICU management of patients after subarachnoid hemorrhage (SAH), especially with regards to hemodynamic management, methods of improving neurological outcomes, and management of cardiac and pulmonary complications. Recent findings Several hemodynamic monitors and parameters may be useful for guiding volume therapy, including cardiac output, stroke volume variation monitoring, and global end-diastolic volume index. Early goal-directed hemodynamic therapy after SAH has recently been shown to improve clinical outcomes in patients with a poor clinical grade or coexisting cardiopulmonary complications. Recent laboratory and imaging modalities are being developed to identify patients at risk for developing vasospasm after SAH. Evidence for the use of various prophylactic adjuvant therapies to prevent vasospasm, including magnesium, phosphodiesterase 3 inhibitors, and therapeutic hypothermia, is emerging. Intrathecal administration of vasodilators or fibrinolytics may have offered advantages over systemic drug administration in the treatment of vasospasm. Pulmonary and cardiac complications are common after SAH, and are associated with an increased risk of mortality. Summary The postoperative ICU period after SAH is associated with a significant morbidity and mortality risk, and recent studies have greatly contributed to our understanding of how to optimally manage these patients.

show abstract

Vasopressin and oxytocin in CSF and plasma of patients with aneurysmal subarachnoid haemorrhage

Cited by 37 publications

References 52 publications

Plasma and Urinary Oxytocin Trajectories in Extremely Premature Infants During NICU Hospitalization

Plasma and Urinary Oxytocin Trajectories in Extremely Premature Infants During NICU Hospitalization

Intranasal Oxytocin: Myths and Delusions

Postoperative ICU management of patients after subarachnoid hemorrhage

Contact Info

Product

Resources

About